Image: PetCure Oncology

PetCure Oncology Treats 1,000th Patient in Battle Against Pet Cancer

Chicago, IL – September 5, 2017 – Since treating their first pet with cancer in 2015, PetCure Oncology has been working tirelessly to care for more pets – and a wider variety of pet cancers – than what was previously possible with traditional cancer care techniques.

8-year-old Sydney is one of many pets that has benefitted from accessibility to SRS through PetCure Oncology.

Less than 30 months later, PetCure Oncology is proud to announce that its 1,000th patient was treated on Tuesday. Sydney, an 8-year-old Boxer mix from Indianapolis, received stereotactic radiosurgery (SRS) for a tumor affecting her central nervous system. Sydney is receiving care from PetCure Oncology at Care Center in Cincinnati, Ohio, one of the few facilities capable of providing SRS for pets.

“This is really a tremendous milestone, not only for PetCure Oncology, but for anybody that works in veterinary cancer care,” said Dr. Neal Mauldin, PetCure’s chief medical officer and a triple-board certified veterinary specialist. “It has been amazing, gratifying, and humbling all at once to see the pets and families that have benefitted from SRS as PetCure Oncology has expanded its footprint. There is nothing better than talking to a pet owner that has just been given more time – and quality time – with their pet.”

Just over two years ago, PetCure was founded by a frustrated pet parent determined to provide pets with access to the same advanced cancer treatments available to humans. That mission has led to the integration of SRS into veterinary medicine, providing pet owners across the country with access to advanced radiation therapy delivered with sub-millimeter precision unprecedented in veterinary medicine.

Of the first 1,000 patients treated by PetCure, nearly 70 percent have benefitted from SRS. Pet owners are electing this potentially life-saving treatment because of its significant benefits over conventional radiation therapy or surgery. SRS, which can target some tumors previously considered “untreatable” by radiation, typically results in improved quality of life and minimal side effects. It is delivered in just 1-3 treatments, an 80-95 percent reduction in both treatment sessions and anesthetic events, leading to decreased risk for the pet patient and increased convenience for the pet owner.

“I can’t say enough about how proud I am of the entire PetCure team, our partner hospitals, and the pet owners who are out there helping us spread the good word every day,” said Scott Milligan, the CEO who created PetCure after his family’s golden retriever fell victim to a nasal tumor. “Today is about more than just a big number. Cancer’s impact reaches far beyond the patient. Today, I am grateful that we have been able to help 1,000 families turn the devastation of a cancer diagnosis into hope for a better outcome.”

With the most experienced network of board-certified veterinary radiation oncologists in the country utilizing the most advanced technology available, PetCure Oncology is making a meaningful impact on the lives of pet families from coast to coast. PetCure has further bolstered its support of pet owners by forming a Pet Advocate Team that is exclusively dedicated to helping owners of pets with cancer.

Pet Advocates are easily reachable by calling 833-PET-HERO or visiting PetCureOncology.com.

###

Media Contact: Jack Moore | Chief Marketing Officer | PetCure Oncology | 847.420.5594 | JMoore@PetCureOncology.com

Published September 5, 2017 | By PetCure Oncology


0 Comments


BACK TO TOP